Axa’s Forte Biosciences FBRX Stock Holding History

Axa’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-649	Closed	-$2.64M	–	1307
2019 Q1	$2.64M	Hold	649	–	–	0.01%	799
2018 Q4	$2M	Buy	+649	New	+$2.8M	0.01%	827

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Axa's FBRX Position: Q2 2019 in Review

Axa sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 649 shares — an estimated $2.64M sold.

Axa first reported a position in FBRX in Q4 2018 and held it in 2 quarters. The position peaked at $2.64M in Q1 2019. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

Axa reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
Axa sold 649 Forte Biosciences shares in Q2 2019, an estimated $2.64M.
Axa first reported a position in Forte Biosciences in Q4 2018 and held it in 2 quarters.
Axa's Forte Biosciences position peaked at $2.64M in Q1 2019.
74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.